e - therapeutics - Enters phase I clinical trial in brain cancer
Wed, 20 Jun 2012 7:45pm
Mon, 29 Apr 2013 10:30pm
Dr Daniel Elger, Chief Financial Officer 

Daniel Elger, Chief Financial Officer
Daniel Elgar, CFO of e-Therapeutics, announces the commencement of clinical trials for the ETS2101 compound as a treatment for brain cancer. Results are expected by the end of 2012 and throughout 2013. MORE
PDF Download
Copyright 2013 BRR Media
AU
UK
E-THERAPEUTICS
E-Theraputics - Interview at Master Investor